background
alloimmunemedi
lung
syndrom
allolss
lifethreaten
complic
hematopoiet
cell
transplant
hct
respiratori
viru
rv
suggest
play
role
pathogenesi
object
studi
relat
rv
dnarna
detect
upperlow
airway
hct
occurr
allolss
method
retrospect
analyz
hct
recipi
realtim
pcr
rv
perform
nasopharyng
aspir
npa
bronchoalveolar
lavag
bal
fluid
hct
main
outcom
interest
presenc
allol
defin
idiopath
pneumonia
syndrom
bronchiol
obliteran
syndrom
outcom
overal
surviv
treatmentrel
mortal
use
cox
proport
hazard
model
logist
regress
model
finegray
compet
risk
regress
analys
result
one
hundr
seventynin
children
median
age
year
includ
rv
found
bal
fluidnpa
npa
rhinoviru
frequent
detect
rv
allolss
occur
rv
posit
bal
fluid
predictor
allolss
hazard
ratio
ci
p
wherea
rv
posit
npa
predictor
found
grade
ii
ivacut
graftversushost
diseas
relat
steroid
treatment
show
trend
toward
protect
effect
odd
ratio
ci
p
allolss
significantli
increas
treatmentrel
mortal
allolss
nonallolss
p
conclus
result
show
prehct
bal
fluid
rv
posit
predictor
allolss
screen
rv
hct
might
identifi
patient
risk
allolss
could
implic
prevent
treatment
might
subsequ
influenc
outcom
hct
j
allergi
clin
immunol
fig
probabl
trm
patient
without
allolss
b
probabl
overal
surviv
os
patient
without
allolss
j
allergi
clin
immunol
februari
versluy
et
al
allogen
hematopoiet
cell
transplant
hct
cur
treatment
sever
malign
nonmalign
childhood
diseas
success
limit
toxic
event
pulmonari
complic
contribut
posttransplant
morbid
mortal
noninfecti
caus
alloimmunemedi
lung
syndrom
allolss
respons
signific
proport
posttransplant
lung
injuri
pediatr
hct
recipi
grow
interest
role
microbiom
patient
graftversushost
diseas
gvhd
pretransplant
condit
regimen
disrupt
intestin
barrier
gut
flora
show
major
chang
hct
caus
dysregul
intestin
immun
homeostasi
eventu
lead
acut
graftversushost
diseas
agvhd
littl
known
respiratori
microbiom
relat
health
diseas
studi
patient
undergo
lung
transplant
allogen
hct
suggest
presenc
common
cold
virus
earli
transplant
associ
either
graft
reject
lung
transplant
develop
alloimmun
lung
diseas
hct
basi
hypothes
earli
presenc
virus
respiratori
tract
caus
tissu
damag
result
activ
alloimmun
system
howev
distinguish
allolss
progress
viral
infect
remain
point
controversi
assess
effect
common
cold
virus
develop
allolss
perform
retrospect
analysi
relat
presenc
viral
dnarna
either
nasopharyng
aspir
npa
bronchoalveolar
lavag
bal
fluid
variou
outcom
paramet
allolss
surviv
includ
consecut
pediatr
patient
receiv
first
allogen
hct
januari
octob
underw
routin
bal
nasal
aspir
accord
previous
describ
prehct
screen
protocol
consist
chest
highresolut
comput
tomographi
hrct
pulmonari
function
test
pft
children
year
age
nasal
aspir
viral
test
bal
viral
bacteri
fungal
diagnost
clinic
data
collect
prospect
start
condit
regist
clinic
databas
minimum
followup
surviv
patient
month
patient
includ
data
collect
written
inform
consent
obtain
accord
declar
helsinki
institut
ethic
committe
approv
sampl
data
collect
obtain
trial
number
bal
perform
achiev
gener
anesthesia
patient
procedur
requir
anesthesia
plan
ie
central
line
placement
hrct
younger
children
instil
ml
normal
salin
aliquot
endotrach
cathet
wedg
distal
bronchi
patient
underw
bal
except
patient
gener
anesthesia
patient
underw
nasal
aspir
pair
bal
sampl
taken
nasal
aspir
done
dispos
cathet
connect
mucou
trap
dri
nasopharyng
suction
perform
follow
instil
immedi
suction
ml
steril
normal
salin
cathet
realtim
pcr
rv
perform
describ
previous
detect
rna
virus
cdna
synthes
multiscrib
revers
transcriptas
random
hexam
appli
biosystem
foster
citi
calif
detect
viral
pathogen
perform
parallel
use
realtim
pcr
assay
specif
follow
virus
bocaviru
human
herpesviru
respiratori
syncyti
viru
influenza
viru
b
parainfluenza
viru
rhinovirus
adenovirus
human
coronavirus
human
metapneumoviru
mycoplasma
pneumonia
semiquantit
viral
load
express
cycl
threshold
ct
valu
case
posit
rv
result
postpon
hct
procedur
week
elect
hct
nonprimari
immunodefici
benign
disord
andor
prolong
immunosuppress
therapi
hct
allol
prophylaxi
fit
hypothesi
rv
posit
predictor
allolss
steroid
treatment
agvhd
protect
effect
occurr
allolss
apart
prehct
screen
routin
monitor
rv
perform
case
onsetprogress
respiratori
symptom
nasal
aspir
bal
repeat
condit
regimen
perform
accord
intern
protocol
patient
nonmalign
diseas
thu
consist
target
busulfan
area
curv
mg
hl
day
fludarabin
mgm
day
patient
malign
diseas
either
fraction
totalbodi
irradiationbas
condit
gy
etoposid
mgkg
target
busulfan
area
curv
mg
hl
plu
fludarabin
mgm
fludarabin
plu
clofarabin
mgm
given
depend
patient
age
myeloid
lymphoid
origin
diseas
central
nervou
system
involv
highrisk
diseas
characterist
patient
receiv
unrel
donor
transplant
serotherapi
perform
antithymocyt
globulin
thymoglobulin
patient
highrisk
malign
relaps
myeloid
leukemia
earli
relaps
lymphoid
leukemia
receiv
cord
blood
cb
donor
omit
antithymocyt
globulin
decemb
onward
stool
sampl
nosethroat
swab
cultur
weekli
monitor
bacteri
colon
plasma
test
weekli
presenc
ebv
cytomegaloviru
human
herpesviru
adenoviru
dna
use
realtim
pcr
weekli
galactomannan
test
platelia
aspergillu
enzym
immunoassay
biorad
laboratori
hercul
calif
perform
screen
aspergillu
speci
infect
antimicrobi
prophylaxi
involv
daili
ciprofloxacin
fluconazol
neutropenia
addit
prophylaxi
streptococcu
viridan
cefazolin
mucos
phase
pneumocysti
jirovecii
pneumonia
prophylaxi
administ
cotrimoxazol
time
week
case
posit
serolog
result
herp
simplex
viru
patient
varicella
zoster
viru
cb
recipi
prophylaxi
acyclovir
given
antivir
prophylaxi
given
highrisk
patient
invas
fungal
infect
aspergillu
speci
prophylaxi
done
daili
voriconazol
twiceweekli
amphotericin
b
gvhd
prophylaxi
consist
cyclosporin
level
mgl
patient
cb
recipi
ad
prednisolon
mgkgd
day
patient
receiv
unrel
volunt
donor
transplant
methotrex
short
cours
mgm
day
ad
cyclosporin
also
administ
short
cours
methotrex
patient
receiv
bone
marrow
hlamatch
sibl
treatment
allolss
consist
mgkgd
intraven
methylprednisolon
day
mgkgd
thereaft
taper
per
week
mgkgd
methylprednisolon
puls
repeat
monthli
recoveri
maximum
puls
recoveri
defin
normal
pft
resolv
symptom
subsequ
puls
mgkgd
prednison
administ
immunosuppress
agent
usual
cyclosporin
continu
addit
azithromycin
given
suggest
immunomodulatori
effect
along
immunosuppress
therapi
support
care
provid
extra
oxygen
mechan
ventil
necessari
main
outcom
interest
occurr
allolss
defin
idiopath
pneumonia
syndrom
ip
bronchiol
obliteran
syndrom
bo
ip
defin
american
thorac
societi
evid
widespread
lung
injuri
clinic
symptom
radiolog
abnorm
absenc
activ
lower
respiratori
tract
infect
factor
explain
pulmonari
dysfunct
cardiac
dysfunct
fluid
overload
renal
failur
bo
defin
accord
nation
institut
health
consensu
criteria
chronic
gvhd
fev
vital
capac
ratio
less
fev
less
evid
airtrap
pft
hrct
scan
absenc
respiratori
tract
infect
adjust
definit
exclud
patient
longer
exist
posit
pcr
result
rv
fulfil
criteria
allolss
describ
previous
addit
investig
associ
allolss
overal
surviv
treatmentrel
mortal
trm
agvhd
chronic
gvhd
organ
classif
accord
glucksberg
criteria
durat
followup
time
develop
allolss
death
last
assess
survivor
assess
associ
outcom
patientrel
variabl
age
transplant
sex
rv
statu
rv
viral
load
express
ct
valu
cytomegaloviru
statu
diseas
malign
bone
marrow
failur
syndrom
inborn
error
metabol
primari
immun
defici
condit
regimen
chemotherapi
totalbodi
irradi
base
donor
factor
stem
cell
sourc
hla
dispar
sampl
size
median
ct
valu
semiquantit
viral
load
taken
dichotom
group
high
low
rv
viral
load
variabl
associ
p
valu
less
use
univari
analysi
select
multivari
analysi
probabl
eventfre
overal
surviv
calcul
use
kaplanmei
estim
use
logrank
test
univari
comparison
timedepend
outcom
analyz
use
cox
proport
hazard
model
end
point
allolss
overal
surviv
trm
use
finegray
compet
risk
regress
dichotom
variabl
univari
multivari
logist
regress
analys
done
statist
analys
perform
either
spss
spss
chicago
ill
r
version
softwar
funder
studi
role
studi
design
data
collect
data
analysi
data
interpret
write
report
bv
jjb
full
access
data
studi
final
respons
decis
submit
public
total
patient
underw
transplant
studi
period
one
hundr
seventynin
patient
pair
npa
bal
sampl
hct
avail
analysi
evalu
studi
patient
npa
bal
fluid
taken
median
age
transplant
year
rang
year
half
patient
underw
transplant
malign
diseas
cb
main
sourc
stem
cell
follow
bone
marrow
baselin
characterist
shown
tabl
median
followup
surviv
patient
year
rang
year
overal
rv
detect
patient
bal
fluid
rv
detect
sampl
children
rv
detect
npa
patient
posit
bal
fluid
rv
result
neg
npa
rv
result
rhinoviru
frequent
detect
rv
follow
multipl
rv
similar
distribut
bal
fluid
npa
shown
tabl
ii
condit
earli
hct
urti
symptom
progress
signific
lower
respiratori
tract
infect
symptom
contrari
patient
recov
spontan
twentyfour
patient
given
diagnosi
allol
median
day
rang
day
fifteen
patient
ip
patient
bo
multivari
analysi
detect
rv
bal
fluid
predictor
associ
allolss
hazard
ratio
hr
ci
p
shown
tabl
iii
see
tabl
articl
onlin
repositori
wwwjacionlineorg
univari
analysi
subdivid
group
bo
ip
similar
result
found
rv
detect
bal
fluid
predictor
bo
hr
ci
p
see
tabl
probabl
allol
year
patient
posit
bal
fluid
rv
result
compar
neg
rv
result
p
fig
presenc
rv
npa
associ
allolss
differ
found
rhinoviru
nonrhinoviru
probabl
allol
develop
fig
b
also
influenc
viral
load
defin
high
low
base
ct
valu
occurr
allolss
see
fig
articl
onlin
repositori
wwwjacionlineorg
patient
rv
bal
fluid
n
determin
associ
occurr
grade
ii
iv
agvhd
treat
system
steroid
occur
median
day
rang
day
develop
allolss
agvhd
appear
protect
develop
allolss
although
result
statist
signific
odd
ratio
ci
p
fig
patient
allolss
treat
immunosuppress
therapi
accord
treatment
guidelin
describ
method
section
ten
patient
aliv
stabil
lung
function
patient
die
relaps
diseas
die
trm
infect
progress
lung
diseas
allolss
contribut
significantli
higher
estim
trm
year
patient
allolss
patient
without
allolss
p
fig
lead
trend
lower
estim
overal
surviv
year
patient
allolss
patient
without
allolss
p
fig
b
knowledg
largest
studi
analyz
associ
detect
rv
dnarna
pediatr
hct
develop
allolss
note
high
incid
rv
prehct
sampl
predominantli
rhinoviru
despit
immunosuppress
treatment
condit
gvhd
prophylaxi
progress
viral
pneumon
occur
median
week
often
coincid
tcell
immun
recoveri
includ
patient
respiratori
symptom
fit
diagnost
criteria
allolss
limit
retrospect
cohort
studi
taken
account
data
suggest
detect
rv
bal
fluid
npa
hct
strong
predictor
develop
allolss
children
hct
differ
effect
found
variou
viral
speci
detect
see
relat
pcr
ct
valu
semiquantit
measur
viral
load
viru
detect
grade
ii
iv
agvhd
anoth
organ
occur
earlier
time
median
onset
week
appear
protect
effect
occurr
allolss
possibl
earlier
initi
increas
immunosuppress
allolss
treat
highdos
steroid
remain
lifethreaten
complic
patient
allolss
significantli
higher
trm
associ
trend
toward
lower
overal
surviv
high
trm
warrant
novel
addit
treatment
prospect
trial
etanercept
one
agent
suggest
other
although
conflict
data
exist
identif
highrisk
patient
prevent
strategi
awar
earli
detect
allolss
could
lead
improv
surviv
chanc
limit
sampl
method
might
possibl
contamin
bronchoscop
rout
upper
airway
influenc
rv
dnarna
posit
bal
sampl
howev
patient
bal
done
tracheal
tube
time
intub
reduc
risk
direct
contamin
moreov
found
differ
ct
valu
npa
bal
fluid
therefor
contamin
seem
unlik
one
would
expect
much
higher
ct
valu
lower
viral
load
contamin
posit
bal
sampl
contamin
suggest
associ
bal
fluid
rv
allolss
would
even
stronger
import
note
studi
period
becam
clear
associ
rv
posit
npa
allolss
start
take
prevent
measur
patient
posit
npa
rv
result
postpon
hct
prolong
immunosuppress
therapi
might
influenc
studi
outcom
could
led
observ
decreas
incid
allolss
time
point
discuss
could
fact
diagnost
criteria
allolss
histor
insist
exclus
infecti
caus
data
suggest
presenc
rv
lower
airway
rather
warn
sign
develop
allolss
fact
prehct
presymptomat
bal
sampl
give
new
insight
discuss
show
rv
could
present
week
month
pulmonari
symptom
occur
despit
fact
patient
sever
immunocompromis
era
precis
detect
tool
eg
pcr
surpris
certain
diseas
exclus
criteria
subject
chang
therefor
allow
rv
pcr
posit
definit
allolss
high
incid
rv
pediatr
hct
recipi
line
recent
studi
effect
rv
hct
popul
conflict
group
describ
progress
viral
pneumonia
describ
spontan
recoveri
other
describ
associ
poor
outcom
furthermor
emerg
report
rhinoviru
common
cold
viru
respiratori
microbiom
consist
virus
bacteria
fungi
close
interact
local
system
immun
viral
immunomodul
complex
multidimension
grow
interest
understand
disturb
lead
lung
diseas
especi
field
chronic
inflammatori
diseas
asthma
chronic
obstruct
pulmonari
diseas
copd
data
suggest
similar
process
occur
common
cold
rv
persist
lung
immunedefici
patient
reconstitut
donorderiv
novel
immun
system
concept
fit
current
understand
alloimmun
hct
host
antigenpres
cell
activ
danger
signal
express
damag
tissu
pathogen
lead
alloactiv
cytokin
releas
induc
cycl
inflamm
tissu
damag
therefor
studi
influenc
microbiomeviriom
develop
alloreact
immun
phenomena
hct
great
interest
line
patient
inborn
error
metabol
found
borderlin
predictor
ip
storag
glycosaminoglycan
lung
lead
lowgrad
inflamm
activ
antigenpres
cell
well
effect
viral
infect
inflamm
studi
allograft
set
lung
transplant
recipi
sever
group
found
associ
rv
develop
acut
chronic
allograft
reject
bo
main
limit
longterm
surviv
also
patient
receiv
solidorgan
transplant
evid
infect
play
role
allograft
dysfunct
immunolog
factor
nonimmunolog
compon
recent
studi
rv
ip
hct
seo
et
al
describ
use
current
avail
diagnost
method
retrospect
found
occult
pathogen
major
bal
fluid
sampl
taken
diagnosi
patient
ip
presenc
pathogen
associ
mortal
even
pathogen
uncertain
pulmonari
pathogen
rhinoviru
reconsid
diagnosi
suggest
viral
pneumon
instead
ip
point
possibl
harm
effect
highdos
steroid
case
detect
pathogen
contrast
interpret
find
import
differ
studi
seo
et
al
inform
rv
statu
patient
experi
ip
shown
pediatr
popul
allolss
develop
median
week
first
detect
rv
tcell
reconstitut
therefor
believ
rv
caus
respiratori
deterior
inflammatori
respons
similar
immun
reconstitut
inflammatori
syndrom
patient
hivaid
time
symptom
protect
immunosuppress
therapi
case
gvhd
initi
respons
increas
immunosuppress
support
hypothesi
primari
immunemedi
process
basi
result
would
recommend
thorough
screen
prehct
patient
chest
hrct
bal
search
fungal
infect
also
rva
predictor
allolss
case
rv
posit
would
advis
slower
taper
immun
suppress
hct
close
monitor
respiratori
symptom
followup
prompt
diagnost
treatment
allol
suspect
conclus
find
show
presenc
rv
dna
rna
bal
fluid
hct
strong
predictor
occurr
allolss
week
month
hct
studi
need
unravel
mechan
underli
alloimmun
phenomena
differ
target
organ
hct
determin
role
respiratori
microbiom
recogn
bal
fluid
rv
posit
hct
predictor
allolss
might
clinic
implic
prevent
adapt
immun
suppress
prophylaxi
preemptiv
therapi
earli
recognit
might
also
lead
improv
surviv
chanc
clinic
implic
children
posit
rv
result
bal
fluid
hct
predispos
allolss
screen
import
prevent
treatment
allolss
base
either
prolong
increas
immun
suppress
